Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2012
05/18/2012WO2012040228A3 Aerosol composition for administering drugs
05/18/2012WO2012039691A3 Synergic effect between n- acetylcysteine and a third generation h1 antagonist such as levoceterizine and desloratadine
05/18/2012WO2012039137A3 A nucleic acid having an anti-metabolic syndrome effect
05/18/2012WO2012038980A3 Fused tricyclic compounds as adenosine receptor antagonist
05/18/2012WO2012038512A3 Composition comprising sod, lutein and zeaxanthin
05/18/2012WO2012037411A9 Estrogen receptor modulators and uses thereof
05/18/2012WO2012035544A3 A novel polymorphic form of rifaximin and process for its preparation
05/18/2012WO2012033390A3 Novel thiophene derivative as sglt2 inhibitor and pharmaceutical composition comprising same
05/18/2012WO2012030106A3 Production method of intermediate compound for synthesizing medicament
05/18/2012WO2012029032A3 Heterocyclic compounds as dgat1 inhibitors
05/18/2012WO2012028335A3 Kinases as targets for anti-diabetic therapy
05/18/2012WO2012027710A3 Compounds that modulate intracellular calcium
05/18/2012WO2012024620A3 Autotaxin inhibitors and uses thereof
05/18/2012WO2012024433A3 Compounds that inhibit tau phosphorylation
05/18/2012WO2012024397A3 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
05/18/2012WO2012024396A3 Compositions and methods for delivering nucleic acid molecules and treating cancer
05/18/2012WO2012021291A3 Methods of treating obstructive lung diseases using bitter tastants
05/18/2012WO2012019086A3 Inhibition of lar phosphatase to enhance therapeutic angiogenesis
05/18/2012WO2012018594A3 Plant-derived polysaccharides for delivery of rna-based therapies
05/18/2012WO2012014085A3 Uses of cimiracemate a and related compounds for treating inflammation and modulating immune responses
05/18/2012WO2012012809A3 APPLICATION OF β-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT
05/18/2012WO2012012410A3 Kappa opioid receptor agonists
05/18/2012WO2012011741A3 Novel fusarisetin compounds, and use thereof
05/18/2012WO2012010944A3 Multiple unit tablet composition
05/18/2012WO2012009258A3 Peptidomimetic galanin receptor modulators
05/18/2012WO2012008788A3 Composition containing serine as an active ingredient for the prevention and treatment of fatty liver diseases, and use thereof
05/18/2012WO2012008718A3 Patch for treating and alleviating symptoms of skin diseases accompanied by effusion of blood proteins
05/18/2012WO2012007978A3 Fermented soya based mixture comprising isoflavones- aglicones, equol and lunasil, process for the preparation and uses thereof in food, medical and cosmetic fields
05/18/2012WO2012003418A3 Functionally selective ligands of dopamine d2 receptors
05/18/2012WO2012001494A3 Pharmaceutical compositions comprising paracetamol and process for preparing the same
05/18/2012WO2011163085A3 Method and compositions use for endothelin-1 related kidney diseases
05/18/2012WO2011158108A3 Aryl substituted indoles and their use as blockers of sodium channels
05/18/2012WO2011156674A3 Thioether prodrug compositions as anti-hiv and anti-retroviral agents
05/18/2012WO2011154975A3 Pharmaceutical compositions of metformin
05/18/2012WO2011153429A9 Methods of treatment
05/18/2012WO2011150994A3 Serum and tissue biomarkers of human hcc
05/18/2012WO2011147034A8 Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof
05/18/2012WO2011142620A3 (+)-3-hydroxymorphinan-based polycycle derivatives as neuroprotectants
05/18/2012WO2011139256A3 Stable rosuvastatin formulations
05/18/2012WO2011139107A3 Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and phamaceutical composition comprising the same
05/18/2012WO2011137877A3 A pharmaceutical composition containing solifenacin and a method of its manufacture
05/18/2012WO2011128629A3 Lipid-vectored drug compositions
05/18/2012WO2011128625A3 Divisible oral pharmaceutical compositions
05/18/2012WO2011110930A3 Rifaximin ready-to-use suspension
05/18/2012WO2011091225A3 Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
05/18/2012WO2011049629A9 Methods of making and using compositions comprising flavonoids
05/18/2012WO2011028737A8 Bisphosphonate compositions and methods for treating heart failure
05/18/2012WO2010151095A8 Novel acetylsalicylic acid salts
05/18/2012CA2834882A1 Lisuride, terguride and derivatives thereof for use in the prophylaxis and/or treatment of fibrotic changes
05/18/2012CA2834381A1 Topical organic acid salt compositions suitable for treating infections
05/18/2012CA2817691A1 Metalloenzyme inhibitor compounds
05/18/2012CA2817585A1 Spiro-oxindole mdm2 antagonists
05/18/2012CA2817577A1 Heterocyclic compounds and uses thereof
05/18/2012CA2817547A1 Sheet and liquid combination systems for dermal drug delivery
05/18/2012CA2817541A1 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
05/18/2012CA2817420A1 Combination therapy with an antitumor alkaloid
05/18/2012CA2817337A1 Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
05/18/2012CA2817336A1 Crystalline solifenacin succinate
05/18/2012CA2817331A1 Chromene derivatives and their analoga as wnt pathway antagonists
05/18/2012CA2817319A1 Sgc stimulators
05/18/2012CA2817310A1 Pharmaceutical composition and dosage form comprising dronedarone, and preparation method thereof
05/18/2012CA2817290A1 Compounds and methods for treating pain
05/18/2012CA2817287A1 Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
05/18/2012CA2817263A1 Salts of kukoamine b, preparation method and use thereof
05/18/2012CA2817223A1 Methods of treating cancer
05/18/2012CA2817219A1 Methods of treating cancer
05/18/2012CA2817199A1 Crystalline solids of a metap-2 inhibitor and methods of making and using same
05/18/2012CA2817113A1 Methods of improving mental or physical health conditions in an individual
05/18/2012CA2817100A1 Piperidinone carboxamide azaindane cgrp receptor antagonists
05/18/2012CA2817071A1 Treatment of addiction and impulse-control disorders using pde7 inhibitors
05/18/2012CA2816974A1 Piperidinone carboxamide indane cgrp receptor antagonists
05/18/2012CA2816944A1 Compounds useful for inhibiting chk1
05/18/2012CA2816804A1 Substituted bicyclic carboxamide and urea derivatives as vanilloid receptor ligands
05/18/2012CA2816798A1 Selective glycosidase inhibitors and uses thereof
05/18/2012CA2816769A1 Substituted heteroaromatic carboxamide and urea derivatives as vanilloid receptor ligands
05/18/2012CA2816753A1 N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
05/18/2012CA2816668A1 Prevention of adverse effects caused by cd3 specific binding domains
05/18/2012CA2816609A1 S-t-butyl protected cysteine di-peptide analogs and related compounds
05/18/2012CA2816603A1 Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
05/18/2012CA2816601A1 Dexamethasone combination therapy
05/18/2012CA2816554A1 Use of 2',5'-oligoadenylate derivative compounds
05/18/2012CA2815941A1 Ibat inhibitors for treatment of metabolic disorders and related conditions
05/18/2012CA2815916A1 Combination of bevacizumab and 2,2-dimethyl-n-((s)-6-oxo-6,7-dihydro - 5h-dibenzo[b,d]azepin-7-yl)-n'-(2,2,3,3,3-pentafluoro-propyl)-malonamide for the treatment of proliferativedisorders
05/18/2012CA2815839A1 Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
05/18/2012CA2815749A1 Ibat inhibitors for the treatment of liver diseases
05/18/2012CA2815741A1 Triazole derivatives as ligands for gaba receptors
05/18/2012CA2815698A1 A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
05/18/2012CA2815492A1 Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
05/18/2012CA2815330A1 Pyridine compounds and aza analogues thereof as tyk2 inhibitors
05/18/2012CA2815179A1 Lactam derivatives useful as orexin receptor antagonists
05/18/2012CA2815002A1 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
05/18/2012CA2814998A1 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
05/18/2012CA2814996A1 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
05/18/2012CA2814828A1 Method of treatment for mental disorders
05/18/2012CA2814195A1 Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
05/18/2012CA2813851A1 Liquid pharmaceutical composition for the treatment of a posterior eye disease
05/18/2012CA2813661A1 Pharmaceutical composition, methods for treating and uses thereof
05/18/2012CA2813413A1 Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd)
05/18/2012CA2812669A1 Pyrazole aminopyrimidine derivatives as lrrk2 modulators
05/18/2012CA2812667A1 Triazole derivatives and their use for neurological disorders
1 ... 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 ... 7860